Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Mesenchymal Stem Cells and Cancer
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Mesenchymal Stem Cells and Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 2919

Special Issue Editors

Dr. Krisztián Németh

E-Mail Website
Guest Editor
Semmelweis Egyetem, Budapest, Hungary
Interests: mesenchymal stem cells
Dr. Balazs Mayer

E-Mail Website
Guest Editor
Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Interests: hematopoietic stem cells; mesenchymal stem cells; genodermatoses

Special Issue Information

Dear Colleagues,

The cancer microenvironment consists of several unique cell types, including endothelial cells, various immune cells, and fibroblasts, which have been shown to resemble both phenotypically and functionally to mesenchymal stem cells (MSCs). The role of intratumoral MSCs is complex and has been linked to tumor initiation, tumor growth, angiogenesis, metastasis, and therapy resistance. In this Special Issue, we invite the submission of original research articles and reviews that report on novel roles of MSCs in tumor biology, including interactions with cancer cells, endothelial cells, and immune cells. We are seeking to publish studies that identify unique molecular pathways (cytokines, small molecules, signal transduction pathways, etc.) that govern MSC interactions and may be targeted to combat cancer growth and induce anti-cancer immunity. Research papers that highlight the importance of MSCs in targeted cancer therapies, checkpoint-inhibitor-based immunotherapies, and CAR-T cell therapies are especially welcomed.

Dr. Krisztián Németh
Dr. Balazs Mayer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • microenvironment
  • tumor stroma
  • cancer-associated fibroblast
  • mesenchymal stem cell
  • cancer immunology
  • angiogenesis
  • metastasis
  • targeted cancer therapy
  • checkpoint inhibitor
  • CAR-T cells
  • immunotherapy
  • signal transduction
  • small molecules

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1197 KiB  
Communication
Influence of Human Bone Marrow Mesenchymal Stem Cells Secretome from Acute Myeloid Leukemia Patients on the Proliferation and Death of K562 and K562-Lucena Leukemia Cell Lineages
by Fábio Alessandro de Freitas, Débora Levy, Cadiele Oliana Reichert, Juliana Sampaio-Silva, Pedro Nogueira Giglio, Luís Alberto de Pádua Covas Lage, Marco Kawamura Demange, Juliana Pereira and Sérgio Paulo Bydlowski
Int. J. Mol. Sci. 2024, 25(9), 4748; https://doi.org/10.3390/ijms25094748 - 26 Apr 2024
Viewed by 270
Abstract
Leukemias are among the most prevalent types of cancer worldwide. Bone marrow mesenchymal stem cells (MSCs) participate in the development of a suitable niche for hematopoietic stem cells, and are involved in the development of diseases such as leukemias, to a yet unknown [...] Read more.
Leukemias are among the most prevalent types of cancer worldwide. Bone marrow mesenchymal stem cells (MSCs) participate in the development of a suitable niche for hematopoietic stem cells, and are involved in the development of diseases such as leukemias, to a yet unknown extent. Here we described the effect of secretome of bone marrow MSCs obtained from healthy donors and from patients with acute myeloid leukemia (AML) on leukemic cell lineages, sensitive (K562) or resistant (K562-Lucena) to chemotherapy drugs. Cell proliferation, viability and death were evaluated, together with cell cycle, cytokine production and gene expression of ABC transporters and cyclins. The secretome of healthy MSCs decreased proliferation and viability of both K562 and K562-Lucena cells; moreover, an increase in apoptosis and necrosis rates was observed, together with the activation of caspase 3/7, cell cycle arrest in G0/G1 phase and changes in expression of several ABC proteins and cyclins D1 and D2. These effects were not observed using the secretome of MSCs derived from AML patients. In conclusion, the secretome of healthy MSCs have the capacity to inhibit the development of leukemia cells, at least in the studied conditions. However, MSCs from AML patients seem to have lost this capacity, and could therefore contribute to the development of leukemia. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

35 pages, 3370 KiB  
Review
The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential
by Youssef Slama, Franck Ah-Pine, Mohamed Khettab, Angelique Arcambal, Mickael Begue, Fabien Dutheil and Philippe Gasque
Int. J. Mol. Sci. 2023, 24(17), 13511; https://doi.org/10.3390/ijms241713511 - 31 Aug 2023
Cited by 3 | Viewed by 2280
Abstract
Mesenchymal stem/stromal cells (MSCs) are multipotent cells involved in numerous physiological events, including organogenesis, the maintenance of tissue homeostasis, regeneration, or tissue repair. MSCs are increasingly recognized as playing a major, dual, and complex role in cancer pathophysiology through their ability to limit [...] Read more.
Mesenchymal stem/stromal cells (MSCs) are multipotent cells involved in numerous physiological events, including organogenesis, the maintenance of tissue homeostasis, regeneration, or tissue repair. MSCs are increasingly recognized as playing a major, dual, and complex role in cancer pathophysiology through their ability to limit or promote tumor progression. Indeed, these cells are known to interact with the tumor microenvironment, modulate the behavior of tumor cells, influence their functions, and promote distant metastasis formation through the secretion of mediators, the regulation of cell–cell interactions, and the modulation of the immune response. This dynamic network can lead to the establishment of immunoprivileged tissue niches or the formation of new tumors through the proliferation/differentiation of MSCs into cancer-associated fibroblasts as well as cancer stem cells. However, MSCs exhibit also therapeutic effects including anti-tumor, anti-proliferative, anti-inflammatory, or anti-oxidative effects. The therapeutic interest in MSCs is currently growing, mainly due to their ability to selectively migrate and penetrate tumor sites, which would make them relevant as vectors for advanced therapies. Therefore, this review aims to provide an overview of the double-edged sword implications of MSCs in tumor processes. The therapeutic potential of MSCs will be reviewed in melanoma and lung cancers. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop